(NASDAQ: CING) Cingulate's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Cingulate's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast CING's revenue for 2026 to be $26,472,021, with the lowest CING revenue forecast at $19,954,851, and the highest CING revenue forecast at $32,989,190. On average, 2 Wall Street analysts forecast CING's revenue for 2027 to be $64,365,009, with the lowest CING revenue forecast at $42,881,701, and the highest CING revenue forecast at $85,848,317.
In 2028, CING is forecast to generate $94,254,829 in revenue, with the lowest revenue forecast at $94,254,829 and the highest revenue forecast at $94,254,829.